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A B S T R A C T
In the present work, an attempt has been made to mask the bitter taste of Levetiracetam
using various ion-exchange resins such as Amberlite IRP69 and Duolite AP143. The physi-
cochemical characteristics of the drug–resin complex in the solid state were studied. FT-IR
studies revealed that there is no interaction between drug and resin.The DSC and XRD studies
proved that the drug is in amorphous nature. Using the same concentration of resins, Xanthan
gum as suspending agent in a liquid dosage form for pediatric use was formulated. Evalu-
ation parameters such as drug content, sedimentation volume, re-dispersibility and viscosity
of the prepared suspension were found to be satisfactory. The higher Zeta potential value
indicates the stability of the suspension. Suspension prepared with Duolite AP 143 effi-
ciently masks the bitter taste of Levetiracetam compared to Amberlite IRP69. From the in
vitro drug release, a formulation with 1:2 ratios of resin has shown the maximum release
at the end of 90 minutes. The sustained effect is due to one of the properties of the resin.
The release profile follows zero order kinetics. The results obtained in this work show that
drug–resin complexes effectively masked the bitter taste of Levetiracetam while liquid for-
mulation provides an easier way to administer and to overcome problems with noncompliance
of pediatrics.
© 2016 Beni-Suef University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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1. Introduction
Levetiracetam [(S)-2-(2-Oxopyrrolidin-1-yl) butanamide] is a
second-generation antiepileptic agent useful in the treat-
ment of partial onset and myoclonic seizures (Fig. 1).
Levetiracetam has been classified as a class-I substance ac-
cording to the Biopharmaceutics Classification System (BCS)
by the Food and Drug Administration (FDA), meaning that it
is highly soluble and highly permeable. Levetiracetam has a
short plasma half-life in adults, which is 7 ± 1 hour with a bitter
taste and faint odor (Sharma et al., 2012). A major problem in
the development of an oral dosage form of levetiracetam is its
intensely bitter taste, leading to poor patient compliance (Nabin
et al., 2014). To overcome the above problem, an attempt has
been made to develop a bitterness-covered Levetiracetam sus-
pension for pediatric use. Without changing its safety and
efficacy, a drug’s taste has to be masked and techniques are
being adapted to meet this need, especially for the pediatric
and juvenile patients (Khar and Sohi, 2004).These are as follows:
taste masking with flavors, taste masking by granulation, mi-
croencapsulation, ion exchange resins, solid dispersion method,
and bitterness inhibitor. Among the techniques mentioned
above, taste masking by ion exchange resins was selected.
The use of ion-exchange materials that manifest specific
functions such as drug release only in ionic environment, taste
masked and mucoadhesive properties presents a robust al-
ternative drug delivery system for achieving sustained-
release. Ion exchange materials are water-insoluble polymers
containing exchange groups in repeating positions on the
polymer chain. The drug is not let out from complexes in an
ion-free aqueous medium during storage, but after oral use it
is released gradually through displacement of ions of the same
charge being present in gastrointestinal fluids. As contrasted
to the other drug delivery systems based on physical prin-
ciple, the elution of drugs from complexes depends only on
the ion strength of the gastrointestinal fluids and not on
complex physiological factors (e.g., pH and enzymes) (Yuan
et al., 2014).
Taste masking by drug–resin complexation is achieved when
an ionizable drug reacts with a suitable ion exchange resin to
form a drug–resinate complex (Nanda and Garg, 2002). Ion ex-
change resins (IERs) are high molecular weight polymers with
cationic and anionic functional groups (most common poly-
meric network is a copolymer of styrene and divinylbenzene).
The drug can be bound to the resin by either repeated expo-
sure of the resin to the drug in a chromatography column or
by prolonged contact of the resin with the drug solution (Atyabi
et al., 1996). Drugs are attached to the oppositely charged resin
substrate, forming insoluble adsorbates or resinates through
weak ionic bonding so that the dissociation of the drug–resin
complex does not occur under the salivary pH conditions (Cuna
et al., 2000). This suitably masks the unpleasant taste and odor
of drugs. Drug release from the resin depends on the proper-
ties of the resin and the ionic environment within the GIT (Gao
et al., 2003). Drug molecules attached to the resin are re-
leased by exchanging with appropriately charged ions in the
GIT, followed by diffusion of free drug molecules out of the
resins (Agarwal et al., 2000). In this work, we attempt to develop
a taste masked dosage form of Levetiracetam by employing ion
exchange resins and formulated into suspension. Oral sus-
pension is preferred by many patients because of the ease of
swallowing and the flexibility in the administration. It is par-
ticularly advantageous for children, the elderly and infants; in
the meantime, the unpleasant taste of the bitter medicinal
agents can be overcome by administrating as undissolved par-
ticles. The complex, by virtue of its insoluble nature of the
salivary condition, exhibits no virtual taste due to which even
extremely loses their taste when converted into a drug resi-
nate. The main aim of this study was to develop and
characterize Levetiracetam ion-exchange resin complex and
to prepare a liquid dosage form using natural polymer like
Xanthan gum as a suspending agent.
2. Materials and methods
2.1. Materials
Levetiracetam was obtained as a gift sample from Molecules
Drugs and Research Laboratory, Chennai, India. Amberlite IRP
69 and Duolite AP 143 were obtained as a gift sample from Dow
Chemical Company, France. Sucrose, sorbitol, glycerine, Xanthan
gum, sodium saccharin, methyl paraben, propyl paraben and
pineapple flavor were purchased from S.D. Fine Chemicals
(Mumbai, India). All other chemicals and solvents were of ana-
lytical grade.
2.2. Drug characterization
The melting point of Levetiracetam was measured by the cap-
illary method. Its solubility was determined in various solvents.
The UV spectrum of Levetiracetam was recorded in the range
of 200–400 nm in the solution of 0.1 N HCl (pH 1.2); the wave-
length of maximum absorption (λmax) in this range was found
and then a calibration curve was prepared at that wavelength.
2.3. Purification of ion exchange resin
The resins were purified using the method reported by Irwin
and co-workers (Irwin et al., 1987).The resins (5 g) were washed
successively with deionized water, methanol (50 ml), benzene
(50 ml) and several times with distilled water to eliminate
organic and color impurities. Wet resins were activated by 5 ml
0.1 M HCl and washed several times with deionized water. All
resins were dried overnight in hot air oven at 50 °C and kept
in an amber glass vial.
2.4. Preparation of drug–resin complex
Drug–resin complex was prepared by batch process (Omar
and James, 1989). In total, six drug–resin complexes wereFig. 1 – Chemical structure of Levetiracetam.
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prepared using two different resins such as Amberlite IRP69
and Duolite AP143. Drug:resin ratios of 1:1, 1:2, 1:3 were
weighed and added to deionized water (50 ml) in a glass
beaker and the suspension was stirred on a magnetic stirrer
for 30 min and allowed to stir for another 5 hour at 37 ± 0.5 °C.
The complexes were harvested by vacuum filtration and
washed free of any unbound drug and ions with deionized
water and then dried to constant weight. To determine the
actual loading capacity, the supernatant was analyzed spec-
trophotometrically (Shimadzu UV-1700) at 210 nm.The amount
of drug loaded into complexes was calculated as the differ-
ence between the initial and the remaining amount of drug
in the supernatant.
2.5. Characterization levetiracetam–resin complexes
2.5.1. FTIR spectroscopy
Chemical interaction between the drug and resin was studied
by FTIR spectroscopy (Raghunathan et al., 1981). The IR spectra
of the samples were obtained using a Fourier transform in-
frared spectrometer (Model CARY 630, Agilent Technologies).
Measurements were carried by KBr disk method, and the scan-
ning range was 4000 to 400 cm–1. The result is shown in Fig. 2.
2.5.2. Differential scanning calorimetry (DSC)
The molecular state of the drug in the resinate was evalu-
ated by performing DSC analyses of pure drug and resinate.
DSC curves of the samples were obtained with a differential
scanning calorimeter (Model TAG 1000, Shimadzu). Each sample
was placed in an aluminum pan and then crimped with an alu-
minum cover. The heating rate was 10 °C min−1. All
measurements were performed over 0–500 °C under a nitro-
gen purge at 50 ml min−1. The results are shown in Fig. 3.
2.5.3. X-ray powder diffraction (XRPD)
X-ray diffraction studies of the samples were performed using
an automated X-ray diffractometer (Rigaku, Smartlab) with a
filter Cu K and SC70 radiation detector, voltage 40 kV, current
30 mA, and at a scanning rate of 10 mm/sec. The results are
shown in Fig. 4.
2.6. Drug content
The resinate prepared by the batch process was evaluated for
the drug content (Srikanth et al., 2010). The resinate equiva-
lent to 100 mg of the drug was magnetically stirred with about
70 ml of buffer (pH 1.2) in 100 ml volumetric flask and then
Fig. 2 – FT-IR spectra of Levetiracetam (A), Levetiracetam–Amberlite IRP69 complex (B), Levetiracetam–Duolite AP 143
complex (C), and Levetiracetam–Xanthan gum physical mixture (D).
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Fig. 3 – DSC thermogram of Levetiracetam (A), Levetiracetam–Amberlite IRP 69 complex (B), and Levetiracetam–Duolite AP
143 complex (C).
Fig. 4 – X-ray diffractograms of Levetiracetam (A), Levetiracetam–Amberlite IRP 69 complex (B), and Levetiracetam–Duolite
AP 143 complex (C).
129b en i - s u e f un i v e r s i t y j o u rna l o f b a s i c and a p p l i e d s c i e n c e s 5 ( 2 0 1 6 ) 1 2 6 – 1 3 3
diluted to volume with buffer.The solution was suitably diluted
and analyzed spectrometrically at 210 nm using gastric simu-
lated fluid (pH 1.2) as blank. The results are shown in Table 2.
2.6.1. Taste evaluation of resinate
Time intensity method was used to check the taste of the re-
sinates (Sana et al., 2012). Six human volunteers were selected.
The sample equivalent to a dose of 10 mg was kept in the
tongue for 60 seconds, and the resinates and pure drug were
evaluated for taste, and the volunteers were instructed not to
swallow the drug. Bitterness levels were recorded at 2, 10 and
60 sec. Volunteers were advised to gargle their mouth thor-
oughly with distilled water.
2.6.2. Formulation of suspension
The syrup was prepared by heating between 60 and 80 °C under
constant stirring and the stability of prepared syrup was im-
proved by the addition of preservatives (Varaporn and Greepol,
2008). Xanthan gum mucilage was prepared by adding water
and stirring well to allow it to swell completely. The drug–
resin complex was added into the syrup solution and stirred
for 30 min to allow proper dispersion complex. Then the
Xanthan gum mucilage was added to above bulk syrup solu-
tion and stirred for 30 min. At the end, the flavoring agent was
added and stirred for 5 min. A total of 6 formulations (LS1, LS2,
LS3, LS4, LS5, LS6) were prepared using two different resins (1:1,
1:2, 1:3); all the formulations contain 70% sorbitol, 0.5% sucrose,
0.1% Xanthan gum, 0.01% methylparaben, 0.05% propylpara-
ben, 0.2% sodium saccharin and pineapple flavor.
2.6.3. Characterization of developed oral taste masked
suspension of levetiracetam
2.6.3.1. Evaluation parameters. All the developed batches of
suspension were evaluated for organoleptic properties such
as color, odor and taste. The pH of the suspension was deter-
mined by using the pH meter. The sedimentation ratio and re-
dispersibility are also measured (Varaporn and Greepol, 2008).
2.6.3.2. In vitro dissolution study of oral taste masked
suspension. The dissolution studies (Ogger and Noory, 1991)
of the suspension were performed using USP-type II dissolu-
tion apparatus (ETC 116, Electro Lab). Suspension equivalent
to 100 mg was transferred in each flask of dissolution appa-
ratus containing 900 ml of buffer (pH 1.2) thermostatically
maintained at 37 ± 0.5 °C at a rotation speed of 100 rpm. At ap-
propriate intervals, 5 ml of the sample was withdrawn and
filtered through 0.45 μm membrane filter, replaced with dis-
solution medium to keep a constant volume. The filtrate was
analyzed by UV-Visible spectrophotometer at 210 nm. The
release profile is shown in Fig. 5.
2.6.3.3. Zeta potential and viscosity. A number of factors
contribute to disperse phase stability in the suspension and
these may be thermodynamic or kinetic in origin. Examples
of the former include steric and electrostatic stabilization,
which induce stability through particle repulsion, while kinetic
stability can be induced by increasing the viscosity of the
suspending medium, thus slowing down particle aggregation
and sedimentation (Larsson et al., 2012). Zeta potential is an
important and useful indicator of the charge that can be
used to predict and control the stability of colloidal suspen-
sions. Zeta potential values (HORIBA Scientific SZ-100) and
its stability behavior are shown in Table 1 and Fig. 6. The
viscosity of the suspension was determined at ambient con-
dition using DV III + , Brookfield Programmable Rheometer,
values shown in Table 2.
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Fig. 5 – In vitro drug release profile of formulation (LS1–LS6).
Table 1 – Zeta potential values and its stability behavior.
Zeta potential [mV] Stability behavior
From 0 to ±5 Rapid coagulation or flocculation
From ±10 to ±30 Incipient instability
From ±30 to ±40 Moderate stability
From ±40 to ±60 Good stability
More than ±61 Excellent stability
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3. Results and discussion
The melting point of Levetiracetam was found to be 118–
121 °C and freely soluble in water. UV analysis of Levetiracetam
in 0.1 N HCl showed an absorption maximum at 210 nm. Se-
lected excipients were checked for their compatibility with the
drug and were analyzed by FT-IR spectra. The Levetiracetam
FT-IR spectra have shown N—H stretching (3349 cm−1), C—H
stretching (2892 cm−1), C—H bending (1426 cm−1), amide C=O
(1642 cm−1), and C—N stretching (1083 cm−1). The same peaks
were found in the FT-IR spectra of resin complexes and drug–
Xanthan gum physical mixture, ensuring that there is no change
of drug form in the formulation, and thus concluding suitabil-
ity of selected resins and excipients.The additional peaks were
found in drug–resin complexes and there are no changes
in the drug peak, concluding that complexes were formed and
there are no changes in drug nature.
The thermogram of pure levetiracetam exhibited a sharp
endothermic peak at 119 °C corresponding to its melting point.
The Amberlite IRP69–levetiracetam complex exhibited a broad
endothermic peak at 126 °C and Duolite AP143–levetiracetam
complex exhibited a broad peak at 117.6 °C. The DSC thermo-
gram of resin complex showed identical peaks corresponding
to the pure drug, but not a sharp endothermic peak, indicat-
ing that the drug is uniformly dispersed and in an amorphous
state.
The X-ray powder diffractogram pattern of levetiracetam
revealed several diffraction peaks which are indicative
of its crystalline character. The diffraction pattern of the
Levetiracetam–Amberlite complex with a marked decrease in
the intensity of the diffraction peaks can be attributed to the
Fig. 6 – Zeta potential of Levetiracetam suspension containing Amberlite IRP 69 (A) and Duolite AP 143(B).
Table 2 – Evaluation parameters of Levetiracetam suspension with different resins.
Parameters LS1 LS2 LS3 LS4 LS5 LS6
Drug content (%) 98.41 ± 0.32 97.52 ± 0.47 96.21 ± 0.56 99.42 ± 0.78 98.52 ± 0.85 98.71 ± 0.39
pH 7.9 8.0 7.8 7.9 8.0 8.1
Sedimentation ratio 0.92 0.93 0.94 0.95 0.98 0.7
Viscosity (cps) 1146 1260 612 432 2070 1080
Taste Slightly bitter taste No bitterness No bitterness No bitterness No bitterness No bitterness
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amorphous character of the ion exchange resins. However, in
the case of Levetiracetam–Duolite complex system, it could be
observed that the diffraction pattern completely diffuse, which
revealed its amorphousness when compared to Amberlite
complex.
The organoleptic properties of the suspension such as color,
odor and taste were found to be satisfactory. Brownian motion
is usually significant to maintain the particles in a dispersed
phase; however, for larger particles, the effect of gravity becomes
significant if there is a sizeable difference in the density between
dispersed and continuous phases. Sedimentation ratio is greater
than unity; some degree of sedimentation can be expected while
a ratio less than unity is likely to indicate a stable system. The
sedimentation ratio of all the formulations (LS1–LS6) was found
to be nearer to one, indicating good stability. Good re-
dispersibility was observed in all the formulations.The prepared
suspension (LS1–LS6) showed 96.21 ± 0.56 to 99.42 ± 0.78 % of
drug content. The result shows that the drug–resin complex
retains its drug loading capacity in the liquid dosage form. The
results are shown in Table 2.
The dissolution study was conducted for 90 minutes to attain
complete release from all the formulations. Formulations LS1,
LS2 and LS3 were prepared by adding Levetiracetam–Amberlite
IRP 69 complex in the ratio of 1:1, 1:2, 1: 3 respectively. For-
mulations LS4, LS5 and LS6 were prepared by adding
Levetiracetam–Duolite AP 143 complex in the ratio of 1:1, 1:2,
1: 3 respectively. In all the formulations, the same concentra-
tion of suspending agent is maintained. To study the effect of
various concentrations of resins in relation to drug release three
different ratios of resins were selected. Formulations LS1, LS2
and LS3 showed drug release of 98.6%, 99.6% and 98.2% at the
end of 45, 60 and 90 minutes respectively. Formulation LS3
showed sustained effect on drug release. Formulations LS4, LS5
and LS6 showed drug release of 99.4%, 99.7% and 89.6% at the
end of 60, 90 and 90 minutes respectively. Formulation LS5, in
the ratio of 1:2 drug–resin complex, showed complete release
at the end of 90 minutes. From the drug release data, it was
revealed that by increasing the concentration of resins drug
release is in a controlled manner, i.e., one of the properties of
resins.The in vitro release data obtained from formulation fitted
with kinetic modeling follows zero order kinetics.
Being in liquid dosage form, stability parameters are to be
considered. The formulation LS5 containing Duolite complex
had a greater viscosity of 2070 centipoise when comparing to
formulation LS3 containing Amberlite complex (Table 2). The
formulations LS3 and LS5 were subjected to Zeta Potential mea-
surement, because to prevent particles from becoming
aggregated it is necessary to provide some barrier. The size of
the potential barrier can be indicated by the magnitude of the
zeta potential, which is the potential at the slipping plane
between the particle and associated double layer with the sur-
rounding solvent. If all the particles in suspension have a large
negative or positive zeta potential, they tend to repel each other
and there will be no tendency for the particles to come to-
gether. The general dividing line between stable and unstable
suspensions is generally taken as +30 or −30mV, with par-
ticles having zeta potentials outside of these limits normally
considered stable. The zeta potential values of formulations
LS3 and LS5 were found to be −126.5 mV and −60.4 mV
respectively.
The formulation LS5 containing Duolite AP143 is consid-
ered to be the best formulation because it has highly amorphous
nature, masked the bitter taste efficiently, good stability be-
havior with greater viscosity and optimum zeta potential value.
4. Conclusion
The complexation with ion exchange resin is a simple and cost-
effective technique for taste masking. Physiochemical
characterizations of prepared complexes were studied. The ef-
ficient taste masking was obtained from drug–resin complex
and formulated as an oral suspension for better patient com-
pliance. The stability behavior of the suspension was studied.
The results obtained in this work show that drug–resin com-
plexes effectively masked the bitter taste of Levetiracetam while
the stable liquid formulation provides an easier way to ad-
minister and to overcome problems with noncompliance of
pediatrics.
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